China Pharma Holdings (CPHI) Current Deferred Revenue (2010 - 2026)

China Pharma Holdings (CPHI) has reported Current Deferred Revenue for 17 consecutive years, with $153642.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Deferred Revenue rose 97.78% year-over-year to $153642.0; the trailing twelve-month figure through Jun 2026 stood at $153642.0 (up 97.78% YoY), and the FY2025 full-year result was $111580.0, down 31.21% from the prior year.
• Current Deferred Revenue advanced to $153642.0 in Q2 2026 per CPHI's latest filing, from $61746.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $520295.0 in Q4 2022 and bottomed at $24920.0 in Q3 2024.
• Historically, Current Deferred Revenue has averaged $132213.9 across 5 years, with a median of $113396.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue plunged 85.52% in 2024, then jumped 385.2% in 2025.
• Over 5 years, Current Deferred Revenue stood at $520295.0 in 2022, then tumbled by 82.6% to $90507.0 in 2023, then jumped by 79.22% to $162208.0 in 2024, then plunged by 31.21% to $111580.0 in 2025, then jumped by 37.7% to $153642.0 in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $153642.0, $61746.0, and $111580.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.